Cancer Immunotherapy: A New Target Emerges as Cells ‘Barf’ Proteins Researchers have identified a surprising location for a key protein, Src, on the surface of cancer cells – a place it shouldn’t be. This discovery, reported in Science, could unlock new avenues for immunotherapy, particularly for solid tumors, which have historically been hard to treat … Read more
Medicare Advantage: A $76 Billion Surplus and a Looming Political Battle The federal government is on track to spend 14% more to cover individuals enrolled in Medicare Advantage (MA) plans compared to those in traditional Medicare – a staggering $76 billion surplus directed towards health insurance companies, according to a recent report by the Medicare … Read more
FDA Under Scrutiny: A Potential Shift in Rare Disease Drug Approvals Senator Ron Johnson (R-Wis.) has launched an investigation into the Food and Drug Administration’s (FDA) rejections of treatments for rare diseases, signaling growing concern over the agency’s decision-making process. The senator is specifically requesting access to the complete response letters – official rejections – … Read more
The Growing Conflict Between Corporate Medicine and Independent Practice The healthcare landscape is witnessing a renewed clash between large hospital systems and independent physician groups, exemplified by a current battle in Oregon. This dispute, as reported by Tara Bannow, centers on the state’s recently revised ban on corporate medicine – a law designed to protect … Read more
FDA Vaccine Chief’s Exit Signals a Potential Shift in Regulatory Scrutiny The recent departure of Dr. Vinay Prasad, the Food and Drug Administration’s (FDA) vaccine chief, marks a potentially significant moment for the agency and the pharmaceutical industry. Prasad’s second exit from the FDA, confirmed on March 6, 2026, follows a period of controversial decisions … Read more
Cognito’s $105 Million Raise: A Glimpse into the Future of Neurological Treatment Cognito Therapeutics’ recent $105 million Series C funding round, led by Morningside Ventures, IAG Capital Partners, and Starbloom Capital, signals growing investor confidence in the potential of non-invasive brain stimulation as a treatment for neurodegenerative diseases. The company, which has now raised $233 … Read more
Moderna’s $2.25 Billion Patent Settlement: A Turning Point for mRNA Technology? Moderna has reached an agreement to pay Roivant Sciences up to $2.25 billion to resolve a long-standing patent dispute concerning the technology crucial to its COVID-19 vaccine, Spikevax. This settlement, involving subsidiaries Genevant Sciences and Arbutus Biopharma, marks a significant moment for the future … Read more
The Future of Organ Creation: Stem Cells, Embryo Models, and the Ethical Frontier The quest to replace failing organs has long driven medical innovation. Now, a modern wave of research – focused on engineering human embryo models using stem cells – is rapidly accelerating, promising potential breakthroughs while simultaneously raising complex ethical questions. These aren’t … Read more
Trump’s Drug Pricing Deals: A Three-Year Window for Change? President Trump’s push for lower prescription drug prices, often touted through “most-favored nation” (MFN) deals with pharmaceutical companies, continues to be a subject of scrutiny. Recent Securities and Exchange Commission (SEC) filings reveal a key detail previously undisclosed: at least some of these agreements are set … Read more
Minnesota’s 340B Drug Pricing Program: A Glimpse into the Future of Drug Discounts A recent report from the Minnesota Department of Health reveals that hospitals and clinics participating in the 340B Drug Pricing Program generated at least $1.34 billion in revenue in 2024. The program, a federal initiative allowing eligible healthcare providers to purchase discounted … Read more